KTTA
NASDAQPasithea Therapeutics Corp.
$0.69-0.02 (-2.99%)
News25/Ratings1
Price$0.69-0.02 (-2.83%)
02:00 PM07:45 PM
News · 26 weeks46+100%
2025-10-262026-04-19
Mix1490d
- Other8(57%)
- SEC Filings5(36%)
- Insider1(7%)
Latest news
25 items- PRPasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)MIAMI, April 20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to PAS-004 for treatment of Neurofibromatosis type-1 (NF1). The FDA grants RPDD for serious or life-threatening diseases in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years and affect fewer than 200,000 people in the U.S. There are approximately 115,000 individuals in the U.S living with NF1. Under the
- INSIDERSEC Form 3 filed by new insider Coastlands Capital Lp3 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.SCHEDULE 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)
- PRPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant MorbidityMIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PAS-004 for the treatment of NF1-associated PN causing significant morbidity. "We appreciate the FDA's decision that PAS-004 meets the criteria for Fast Track designation for this indication," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. "The ability to have early and frequent interactions with the FDA supports our goal to expeditiously develop PAS-004
- SECSEC Form 10-K filed by Pasithea Therapeutics Corp.10-K - Pasithea Therapeutics Corp. (0001841330) (Filer)
- SECPasithea Therapeutics Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pasithea Therapeutics Corp.SCHEDULE 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)
- SECSEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.SCHEDULE 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)
- PRPasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –– Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced that Chief Executive Officer Tiago Reis Marques will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026. The Company's presentation is scheduled for Thursday, Feb 26 at 4:00-4:30 PM ET in Track 2,
- SECSEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.SCHEDULE 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)
- SECSEC Form S-8 filed by Pasithea Therapeutics Corp.S-8 - Pasithea Therapeutics Corp. (0001841330) (Filer)
- SECPasithea Therapeutics Corp. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)
- SECSEC Form EFFECT filed by Pasithea Therapeutics Corp.EFFECT - Pasithea Therapeutics Corp. (0001841330) (Filer)
- SECSEC Form POS AM filed by Pasithea Therapeutics Corp.POS AM - Pasithea Therapeutics Corp. (0001841330) (Filer)
- PRPasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release TimelinesMIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN), today provided updated timelines on its ongoing clinical trials in advanced cancer and adult NF1-PN patients. Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565): Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets) in Part A of the study. The Company plans to present data in the second half of
- SECSEC Form DEF 14A filed by Pasithea Therapeutics Corp.DEF 14A - Pasithea Therapeutics Corp. (0001841330) (Filer)
- SECSEC Form PRE 14A filed by Pasithea Therapeutics Corp.PRE 14A - Pasithea Therapeutics Corp. (0001841330) (Filer)
- SECPasithea Therapeutics Corp. filed SEC Form 8-K: Other Events8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)
- SECSEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.SCHEDULE 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)
- SECPasithea Therapeutics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)
- PRPasithea Therapeutics Announces Closing of $60 Million Public Offering of Common StockExtends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA, KTTAW)), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), today announced the closing of its previously announced public offering of 80,000,000 shares of the Company's common
- INSIDERDirector Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- INSIDERChief Financial Officer Schneiderman Daniel H was granted 26,667 shares (SEC Form 4)4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- INSIDERChief Executive Officer Marques Tiago bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 83% to 73,334 units (SEC Form 4)4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)
- INSIDERDirector Dumesnil Simon bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 1,333% to 35,833 units (SEC Form 4)4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)